Lab
Regents of the University of
Regents of the University of was paid $2.36M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 9.5% of everything it billed.
33Billing provider infoREGENTS OF THE UNIVERSITY OF
PANORAMA CITY, CA 91402
PANORAMA CITY, CA 91402
33aNPI1871731729assigned 01/30/2009
33bProvider typeClinical Medical Laboratory
28Total paid$2.36M
24GClaims325,500
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#139 of 561
Median peer was paid$222K
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,557 | $48K | |
| 2019 | 13,121 | $36K | |
| 2020 | 20,593 | $124K | |
| 2021 | 36,284 | $303K | |
| 2022 | 42,773 | $459K | |
| 2023 | 74,481 | $711K | |
| 2024incomplete | 113,691 | $676K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 9.5% | 41,754 | 36,296 | $225K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.9% | 1,936 | 1,819 | $140K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.9% | 7,106 | 6,750 | $114K |
| 80061 | Lipid panel | 4.7% | 15,752 | 15,129 | $110K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.4% | 24,053 | 21,592 | $103K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.2% | 2,497 | 2,375 | $99K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.9% | 5,045 | 4,772 | $93K |
| 86481 | 3.8% | 1,507 | 1,487 | $89K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.7% | 16,620 | 15,757 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.7% | 12,318 | 11,949 | $86K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.1% | 587 | 562 | $72K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.0% | 2,338 | 1,810 | $70K |
150 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.0% | 2,323 | $70K |
| 86803 | 2.2% | 5,160 | $52K | |
| 87631 | 1.9% | 838 | $44K | |
| 99000 | 1.8% | 11,599 | $42K | |
| 82728 | 1.3% | 4,750 | $31K | |
| 87340 | 1.3% | 4,078 | $31K | |
| 85027 | 1.3% | 9,663 | $30K | |
| 83735 | 1.2% | 7,856 | $29K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 7,315 | $29K |
| 83970 | 1.2% | 2,022 | $27K | |
| 83880 | 1.1% | 1,409 | $27K | |
| 82746 | 1.1% | 3,467 | $26K | |
| 87536 | 1.1% | 470 | $25K | |
| 82378 | <1% | 3,010 | $23K | |
| 86160 | <1% | 2,693 | $23K | |
| 82570 | <1% | 8,930 | $22K | |
| 83550 | <1% | 4,934 | $21K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 716 | $20K |
| 83540 | <1% | 5,219 | $19K | |
| 86140 | <1% | 5,637 | $18K | |
| 86300 | <1% | 2,360 | $17K | |
| 82607 | <1% | 3,766 | $16K | |
| 84403 | <1% | 1,155 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,360 | $15K |
| 82670 | <1% | 603 | $15K | |
| 84439 | <1% | 3,811 | $15K | |
| 81001 | <1% | 8,921 | $14K | |
| 80197 | <1% | 1,918 | $13K | |
| 82043 | <1% | 5,054 | $12K | |
| 84100 | <1% | 5,844 | $12K | |
| 86225 | <1% | 1,332 | $12K | |
| 86235 | <1% | 1,009 | $11K | |
| 86360 | <1% | 433 | $11K | |
| 87497 | <1% | 552 | $11K | |
| 87505 | <1% | 153 | $10K | |
| 86706 | <1% | 1,278 | $10K | |
| 85610 | <1% | 3,852 | $10K | |
| 85652 | <1% | 6,050 | $9K | |
| 82784 | <1% | 2,648 | $9K | |
| 86038 | <1% | 1,143 | $8K | |
| 86704 | <1% | 875 | $8K | |
| 84156 | <1% | 3,541 | $8K | |
| 87077 | <1% | 2,223 | $7K | |
| 83615 | <1% | 2,933 | $7K | |
| 82274 | <1% | 664 | $7K | |
| 86359 | <1% | 345 | $7K | |
| 84153 | <1% | 941 | $7K | |
| 87186 | <1% | 1,632 | $6K | |
| 87088 | <1% | 1,437 | $6K | |
| 85730 | <1% | 1,660 | $6K | |
| 82550 | <1% | 1,780 | $6K | |
| 86592 | <1% | 1,531 | $6K | |
| 80076 | <1% | 1,096 | $5K | |
| 82105 | <1% | 502 | $5K | |
| 86255 | <1% | 583 | $5K | |
| 87102 | <1% | 756 | $5K | |
| 87070 | <1% | 847 | $5K | |
| 86376 | <1% | 485 | $4K | |
| 86334 | <1% | 604 | $4K | |
| 87808 | <1% | 350 | $4K | |
| 82465 | <1% | 1,394 | $4K | |
| 83520 | <1% | 418 | $4K | |
| 86146 | <1% | 310 | $4K | |
| 82610 | <1% | 389 | $4K | |
| 87205 | <1% | 1,071 | $4K | |
| 87799 | <1% | 236 | $3K | |
| 86800 | <1% | 414 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,820 | $3K |
| 84165 | <1% | 945 | $3K | |
| 86258 | <1% | 437 | $3K | |
| 86147 | <1% | 174 | $3K | |
| 86431 | <1% | 787 | $3K | |
| 82533 | <1% | 383 | $2K | |
| 84481 | <1% | 331 | $2K | |
| 86762 | <1% | 200 | $2K | |
| 86364 | <1% | 307 | $2K | |
| 83690 | <1% | 600 | $2K | |
| 83993 | <1% | 156 | $2K | |
| 86301 | <1% | 216 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 51 | $2K |
| 84550 | <1% | 1,171 | $2K | |
| 86200 | <1% | 506 | $2K | |
| 83721 | <1% | 519 | $2K | |
| 86231 | <1% | 241 | $2K | |
| 85046 | <1% | 620 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 71 | $2K |
| 83521 | <1% | 490 | $2K | |
| 86787 | <1% | 163 | $1K | |
| 83002 | <1% | 127 | $1K | |
| 83001 | <1% | 120 | $1K | |
| 83516 | <1% | 130 | $1K | |
| 83021 | <1% | 93 | $1K | |
| 86039 | <1% | 191 | $1K | |
| 82330 | <1% | 348 | $1K | |
| 84270 | <1% | 205 | $1K | |
| 87517 | <1% | 61 | $1K | |
| 86480 | <1% | 32 | $952.94 | |
| 86765 | <1% | 103 | $938.74 | |
| 82785 | <1% | 83 | $932.22 | |
| 84146 | <1% | 89 | $901.42 | |
| 82024 | <1% | 69 | $873.32 | |
| 82977 | <1% | 219 | $859.24 | |
| 99199 | Unlisted special service, procedure or report | <1% | 16 | $824.09 |
| 82951 | <1% | 74 | $801.08 | |
| 84154 | <1% | 113 | $710.83 | |
| 86036 | <1% | 98 | $696.94 | |
| 84432 | <1% | 118 | $664.23 | |
| 86003 | <1% | 107 | $627.24 | |
| 85613 | <1% | 105 | $577.10 | |
| 82565 | <1% | 320 | $558.28 | |
| 85379 | <1% | 145 | $523.15 | |
| 86708 | <1% | 56 | $482.56 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 17 | $413.00 |
| 80074 | <1% | 14 | $402.13 | |
| 86141 | <1% | 65 | $348.14 | |
| 83010 | <1% | 96 | $316.93 | |
| 84425 | <1% | 95 | $315.90 | |
| 86355 | <1% | 13 | $289.75 | |
| 86357 | <1% | 13 | $289.00 | |
| 83921 | <1% | 83 | $266.20 | |
| 84238 | <1% | 62 | $252.92 | |
| 87206 | <1% | 89 | $242.82 | |
| 83695 | <1% | 61 | $211.40 | |
| 87493 | <1% | 28 | $207.23 | |
| 82150 | <1% | 82 | $183.93 | |
| 84445 | <1% | 12 | $175.00 | |
| 84630 | <1% | 94 | $164.00 | |
| 83519 | <1% | 43 | $158.07 | |
| 87338 | <1% | 27 | $148.59 | |
| 85007 | <1% | 72 | $116.56 | |
| 86705 | <1% | 13 | $106.67 | |
| 82248 | <1% | 36 | $99.63 | |
| 84207 | <1% | 28 | $93.80 | |
| 82523 | <1% | 40 | $84.80 | |
| 84080 | <1% | 27 | $84.39 | |
| 82040 | <1% | 38 | $82.68 | |
| 84681 | <1% | 14 | $76.50 | |
| 86335 | <1% | 12 | $73.06 | |
| 84300 | <1% | 46 | $62.27 | |
| 84460 | <1% | 30 | $59.51 | |
| 84166 | <1% | 28 | $56.86 | |
| 82668 | <1% | 14 | $54.12 | |
| 86833 | <1% | 15 | $39.15 | |
| 86832 | <1% | 15 | $39.15 | |
| 84132 | <1% | 43 | $36.53 | |
| 82085 | <1% | 13 | $34.50 | |
| 83935 | <1% | 15 | $33.53 | |
| 84446 | <1% | 12 | $27.93 | |
| 84590 | <1% | 12 | $27.23 | |
| 85018 | <1% | 12 | $8.98 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALLACE, TAMMY (CHIEF FINANCIAL OFFICER)
Parent organizationTHE REGENTS OF THE UNIVERSITY OF CALIFORNIA
| Provider | Location | Paid |
|---|---|---|
| Regents Univ of Calif Los Angeles | Los Angeles, CA | $41.47M |
| Regents of the Univ of California | Santa Monica, CA | $11.54M |
| Regents Univ of Calif Los Angeles | West Hills, CA | $360K |
| Regents Univ of Calif Los Angeles | Los Angeles, CA | $19K |
| DR Tammy Wallace LLC | Ozark, AL | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.